两种α‐突触核蛋白种子扩增法鉴别帕金森病和非典型帕金森病的比较

IF 7.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders Pub Date : 2025-08-21 DOI:10.1002/mds.70017

Marcello Rossi, Carly M. Farris, Simone Baiardi, Giulia Giannini, Franco Magliocchetti, Luisa Sambati, Yihua Ma, Erica Vittoriosi, Giovanna Calandra‐Buonaura, Luis Concha‐Marambio, Piero Parchi

{"title":"两种α‐突触核蛋白种子扩增法鉴别帕金森病和非典型帕金森病的比较","authors":"Marcello Rossi, Carly M. Farris, Simone Baiardi, Giulia Giannini, Franco Magliocchetti, Luisa Sambati, Yihua Ma, Erica Vittoriosi, Giovanna Calandra‐Buonaura, Luis Concha‐Marambio, Piero Parchi","doi":"10.1002/mds.70017","DOIUrl":null,"url":null,"abstract":"BackgroundSeed amplification assays (SAAs) for misfolded α‐synuclein (syn) have shown inconsistent results in multiple system atrophy (MSA).ObjectiveThe objective of this study was to compare a novel syn SAA (synSAA) that distinguishes between Lewy body disease (LBD) and MSA syn‐seeds (Amprion‐SAA) with an LBD‐specific synSAA (IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB]‐SAA).MethodsWe applied both assays to cerebrospinal fluid samples from 114 patients with MSA, 49 patients with Parkinson disease (PD), 40 patients with progressive supranuclear palsy (PSP), and 46 controls.ResultsAmprion‐SAA detected type 2 (“MSA‐type”) syn‐seeds in 101 (88.6%) MSA, 3 (6.1%) PD, 4 (10.0%) PSP, and 6 (13.0%) control participants, and type 1 (“LBD‐type”) syn‐seeds in 39 (79.6%) PD, 3 (2.6%) MSA, and 1 (2.5%) PSP participant. ISNB‐SAA detected LBD‐specific syn‐seeds in 40 (81.6%) PD, 4 (3.5%) MSA, and none of the PSP or control participants.ConclusionsAmprion‐SAA, performed at ISNB, uniquely discriminated MSA from both PD and PSP participants with good accuracy. However, it showed lower specificity than ISNB‐SAA, primarily related to the type 2 profile. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"38 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism\",\"authors\":\"Marcello Rossi, Carly M. Farris, Simone Baiardi, Giulia Giannini, Franco Magliocchetti, Luisa Sambati, Yihua Ma, Erica Vittoriosi, Giovanna Calandra‐Buonaura, Luis Concha‐Marambio, Piero Parchi\",\"doi\":\"10.1002/mds.70017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BackgroundSeed amplification assays (SAAs) for misfolded α‐synuclein (syn) have shown inconsistent results in multiple system atrophy (MSA).ObjectiveThe objective of this study was to compare a novel syn SAA (synSAA) that distinguishes between Lewy body disease (LBD) and MSA syn‐seeds (Amprion‐SAA) with an LBD‐specific synSAA (IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB]‐SAA).MethodsWe applied both assays to cerebrospinal fluid samples from 114 patients with MSA, 49 patients with Parkinson disease (PD), 40 patients with progressive supranuclear palsy (PSP), and 46 controls.ResultsAmprion‐SAA detected type 2 (“MSA‐type”) syn‐seeds in 101 (88.6%) MSA, 3 (6.1%) PD, 4 (10.0%) PSP, and 6 (13.0%) control participants, and type 1 (“LBD‐type”) syn‐seeds in 39 (79.6%) PD, 3 (2.6%) MSA, and 1 (2.5%) PSP participant. ISNB‐SAA detected LBD‐specific syn‐seeds in 40 (81.6%) PD, 4 (3.5%) MSA, and none of the PSP or control participants.ConclusionsAmprion‐SAA, performed at ISNB, uniquely discriminated MSA from both PD and PSP participants with good accuracy. However, it showed lower specificity than ISNB‐SAA, primarily related to the type 2 profile. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\",\"PeriodicalId\":213,\"journal\":{\"name\":\"Movement Disorders\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Movement Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/mds.70017\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mds.70017","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

错误折叠的α‐突触核蛋白（syn）的种子扩增试验（SAAs）在多系统萎缩（MSA）中显示出不一致的结果。本研究的目的是比较一种区分路易体病（LBD）和MSA syn - seeds （Amprion - SAA）的新型synSAA （synSAA）和一种LBD特异性synSAA （IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB] - SAA）。方法对114例MSA患者、49例帕金森病（PD）患者、40例进行性核上性麻痹（PSP）患者和46例对照组的脑脊液进行两种检测。结果samprion‐SAA在101例（88.6%）MSA、3例（6.1%）PD、4例（10.0%）PSP和6例（13.0%）对照受试者中检测到2型（“MSA型”）syn - seed，在39例（79.6%）PD、3例（2.6%）MSA和1例（2.5%）PSP受试者中检测到1型（“LBD型”）syn - seed。ISNB - SAA在40名PD（81.6%）、4名MSA（3.5%）和PSP或对照参与者中检测到LBD特异性syn - seed。结论在ISNB进行的samprion‐SAA能够准确区分PD和PSP参与者的MSA。然而，它的特异性低于ISNB‐SAA，主要与2型相关。©2025作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparison of Two α‐Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism

BackgroundSeed amplification assays (SAAs) for misfolded α‐synuclein (syn) have shown inconsistent results in multiple system atrophy (MSA).ObjectiveThe objective of this study was to compare a novel syn SAA (synSAA) that distinguishes between Lewy body disease (LBD) and MSA syn‐seeds (Amprion‐SAA) with an LBD‐specific synSAA (IRCCS Istituto delle Scienze Neurologiche di Bologna [ISNB]‐SAA).MethodsWe applied both assays to cerebrospinal fluid samples from 114 patients with MSA, 49 patients with Parkinson disease (PD), 40 patients with progressive supranuclear palsy (PSP), and 46 controls.ResultsAmprion‐SAA detected type 2 (“MSA‐type”) syn‐seeds in 101 (88.6%) MSA, 3 (6.1%) PD, 4 (10.0%) PSP, and 6 (13.0%) control participants, and type 1 (“LBD‐type”) syn‐seeds in 39 (79.6%) PD, 3 (2.6%) MSA, and 1 (2.5%) PSP participant. ISNB‐SAA detected LBD‐specific syn‐seeds in 40 (81.6%) PD, 4 (3.5%) MSA, and none of the PSP or control participants.ConclusionsAmprion‐SAA, performed at ISNB, uniquely discriminated MSA from both PD and PSP participants with good accuracy. However, it showed lower specificity than ISNB‐SAA, primarily related to the type 2 profile. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Movement Disorders 医学-临床神经学

CiteScore

13.30

自引率

8.10%

发文量

371

审稿时长

12 months

期刊介绍： Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.